The present invention relates to a separation of viruses of an essentially spherical shape from viruses with a rod-like shape that are comprised in a sample, wherein the sample comprising the viruses is subjected to filtration.

The present disclosure pertains to methods for separating proteins from surfactants that comprise (a) adding an amount of denaturing buffer to a mixture comprising a protein and a surfactant thereby forming a denatured solution wherein the protein is denatured and (b) filtering the denatured solution with a molecular weight cutoff filter, thereby separating the protein from the surfactant and the denaturing buffer. The present disclosure also pertains to kits for forming such methods.

The present invention relates to a method for purifying viruses or virus-like particles using a crosslinked cellulose hydrate membrane and to a kit for purifying viruses or virus-like particles and the use thereof.

Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.

Methods for producing viruses from adherent cells are provided. The methods include releasing virus from adherent host cells grown in a bioreactor, and purifying released virus by ultrafiltration and/or diafiltration. The methods can be used to manufacture viruses, including for clinical use, at reduced cost relative to conventional virus manufacturing methods.

Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.

The present invention concerns a novel human erythroid progenitor cell line, wherein at least 90% of the cells are CD36.sup.+ CD44.sup.?CD71.sup.+; and wherein the cells:do not express the gene encoding the receptor of Granulocyte-macrophage colony-stimulating factor (GM-CSF-R gene) or express GM-CSF-R gene at a lower level than the cells of human UT-7/Epo-S1 cell line; andexpress the gene encoding the receptor of erythropoietin (Epo-R gene). The present invention also concerns the uses thereof for producing, detecting, or quantifying parvovims B19. The present invention allows the use of the cell lines for 1) a highly sensitive B19 infectious particles detection, and, 2) the efficient production of infectious B19 particles.

Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.

The present invention relates to a separation of viruses of an essentially spherical shape from viruses with a rod-like shape that are comprised in a sample, wherein the sample comprising the viruses is subjected to filtration.

The present invention relates to a method for purifying viruses or virus-like particles using a crosslinked cellulose hydrate membrane and to a kit for purifying viruses or virus-like particles and the use thereof.